| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_015b06914223e1628bc6a0b3d09dcde5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_058fa6879f9b1a775f19483db361140b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-626
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3084
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 |
| filingDate |
2014-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bf91aa0af0f3c32fdade181ceeb0be2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fa5dc0a06af4001a75bd0846f0732a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c5f1cfd59efbd3cc41ccc589ffd499e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8904a625bfcec820ad259741cf771a05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62d761a2ce8d321eadd6ebe2905cb14d |
| publicationDate |
2015-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2014261788-A2 |
| titleOfInvention |
Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells Cancer |
| abstract |
The present disclosure relates to an antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer. The present disclosure further concern a pharmaceutical composition comprising said antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, said method comprising administering said antibody to said patient. The present disclosure also relates to a method for diagnosing a CSC and to the use of the 0-acetylated-GD2 ganglioside as a biomarker of CSC cancer. Finally, the disclosure relates to a method for predicting the response of a subject affected with CSC cancer to a treatment with an antibody or a composition of the invention. |
| priorityDate |
2013-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |